US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 20:46:48 Source:travelViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:MPs' fury at 'virtue
Next:Trump or Biden? Either way, US seems poised to preserve heavy tariffs on imports
You may also like
- Online reading or offline clubs? Young Chinese embrace both in digital era
- Chris Pine again wears his I Love LA T
- Fire severely damages a Los Angeles County fire station
- Tyra Banks reveals she had very first alcoholic drink AFTER turning 50: 'It wasn't worth it!'
- Brewers starter Joe Ross leaves after first inning vs. Marlins with lower back strain
- Zhejiang crush Shanghai to reach CBA semis
- F1 STEM event aims to excite Shanghai's youth in science and tech
- Vegas retaliation on Stars forward Seguin costly as defending champion Knights now trail series
- David Cronenberg's new grief